Any other treatments for prostate cancer are not allowed, including switch or initiation of second-generation androgen receptor axis inhibitors (abiraterone, enzalutamide, darolutamide, apalutamide), taxane- or platin-based chemotherapy (washout period of 6 wk before first cycle of [177Lu]Lu-PSMA-617 RPT), RPT (including 89Sr, 153Sm, 186Re, 188Re, 223Ra; washout of 6 wk before first cycle of [177Lu]Lu-PSMA-617 RPT), sipuleucel-T, olaparib, rucaparib, and pembrolizumab (washout period of 4 wk before first cycle of [177Lu]Lu-PSMA-617 RPT). This evidence concerns the gene FOLH1 and prostate carcinoma.